Page last updated: 2024-12-09

2,6-bis(benzimidazol-2-yl)pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-bis(benzimidazol-2-yl)pyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID738986
CHEMBL ID524786
CHEBI ID188611
SCHEMBL ID1272832
MeSH IDM0484287

Synonyms (38)

Synonym
STL296117
2,2'-pyridine-2,6-diylbis(1h-benzimidazole)
2-[6-(1h-benzimidazol-2-yl)-2-pyridyl]-1h-benzimidazole
1h-benzimidazole, 2,2'-(2,6-pyridinediyl)bis-
SR-01000636096-1
2,6-bis(2-benzimidazolyl)pyridine
B3510
2,2'-(2,6-pyridinediyl)bis(benzimidazole)
AKOS000359634
2,6-bis(2-benzimidazyl)pyridine
28020-73-7
TCMDC-123507 ,
gnf-pf-3082 ,
CHEMBL524786
CHEBI:188611
2-[6-(1h-benzimidazol-2-yl)pyridin-2-yl]-1h-benzimidazole
A5364
2-(6-(1h-benzo[d]imidazol-2-yl)pyridin-2-yl)-1h-benzo[d]imidazole;2,6-bis(benzimidazol-2-yl)pyridine
2-[6-(1h-1,3-benzodiazol-2-yl)pyridin-2-yl]-1h-1,3-benzodiazole
2,6-di(1h-benzo[d]imidazol-2-yl)pyridine
CCG-46396
2,6-bis(benzimidazol-2-yl)pyridine
FT-0638744
2,6-bis(1h-benzo[d]imidazol-2-yl)pyridine
AB00075825-01
JBKICBDXAZNSKA-UHFFFAOYSA-N
SCHEMBL1272832
mfcd00134500
cambridge id 5225128
2?6-bis?2-benzimidazyl)pyridine
DTXSID20353383
AS-61288
J-016946
SY039783
1h-benzimidazole,2,2-(2,6-pyridinediyl)bis
AMY36510
T70711
CS-W009339

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1295126Ionophoric activity assessed as induction of pH discharge across POPC/cholesterol (30%) based liposomal membranes at 1 to 5% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295118Ionophoric activity assessed as induction of chloride influx into EYPC based liposomal membranes at 1 to 5% in presence of intravesicular Na2SO4 by lucigenin based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295112Binding affinity to chloride anion assessed as association constant by spectrometric titration method relative to Me2bimpy2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295111Binding affinity to nitrate anion assessed as association constant by spectrometric titration method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295113Binding affinity to bromide anion assessed as association constant by spectrometric titration method relative to Me2bimpy2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295115Binding affinity to nitrate anion assessed as association constant by spectrometric titration method relative to Me2bimpy2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1295121Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes using chloride salt of Na+ ions at 3% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295125Ionophoric activity assessed as induction of pH discharge across POPC based liposomal membranes at 1 to 5% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295123Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes using chloride salt of Rb+ ions at 3% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1295122Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes using chloride salt of K+ ions at 3% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295108Binding affinity to chloride anion assessed as association constant by spectrometric titration method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295116Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes at 1 to 5% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295124Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes using chloride salt of Cs+ ions at 3% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295117Ionophoric activity assessed as induction of chloride influx into EYPC based liposomal membranes at 1 to 5% in presence of intravesicular NaNO3 by lucigenin based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1295128Ionophoric activity assessed as induction of chloride influx into EYPC based liposomal membranes at 5% measured within 5 mins by lucigenin based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295110Binding affinity to iodide anion assessed as association constant by spectrometric titration method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295120Ionophoric activity assessed as induction of pH discharge across EYPC based liposomal membranes using chloride salt of Li+ ions at 3% by pyranine based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295119Ionophoric activity assessed as induction of chloride influx into EYPC based liposomal membranes at 1 to 5% in presence of intravesicular and extravesicular Na2SO4 by lucigenin based fluorescence assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295114Binding affinity to iodide anion assessed as association constant by spectrometric titration method relative to Me2bimpy2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID1295109Binding affinity to bromide anion assessed as association constant by spectrometric titration method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
2,6-Bis(benzimidazol-2-yl)pyridine as a potent transmembrane anion transporter.
AID602118NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (13.04)29.6817
2010's17 (73.91)24.3611
2020's3 (13.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.97 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]